Talking Medicines co-founder Scott Crae was invited by the Ethical Medicines Industry Group (EMIG) to present on the opportunities for AI tools in a data-driven healthcare environment. EMIG is a multi-stakeholder network and trade association representing the interests of life-science companies in the UK, with over 300 member organisations from academia, research policy, patient organisations, pharma, and life-science sectors.
The session, warmly hosted by Brenda Dooley, Managing Secretariat of EMIG Scotland and Founder and CEO of AXIS Healthcare Consulting Ltd, specialists in Health Technology Assessments across the UK and Ireland, provided an engaging platform for discussing AI in healthcare. Scott was delighted to present Drug-GPT to the group, demonstrating its advanced data science, AI, and natural language interface, and addressing questions about the ethics, transparency, data security, and quality of the intelligence that Talking Medicines offers through Drug-GPT.
Drug-GPT offers deep longitudinal insights by curating and structuring the authored voice of patients, healthcare professionals, and key opinion leaders. This session was a great opportunity to discuss the ethical implications of AI in health, the practical implementation of a ‘healthcare ready’ AI solution, data security, trust, bias, and quality control. Scott shared the work that Talking Medicines has done on the burgeoning GLP-1 antagonist Type 2 Diabetes/Weight Loss arena, highlighting the methodology behind the efficiency and effectiveness of AI tools like Drug-GPT. These tools bring new, rich insights into the patient and HCP experience of drugs and how external factors influence them, through a combination of clear visuals and concise, AI-generated text, accessed by asking natural language questions of the data.
During the session, there were several follow-up questions, and Scott shared his thoughts on fielding replies to such a distinguished audience. He stated, “In my role as a Founder, Partnerships, ESG and Impact are particularly important to me, and to Talking Medicines. We are a socially invested company with a mission to improve patient outcomes through better understanding of the patient and HCP experience of drugs and healthcare. By presenting Drug-GPT to the Ethical Medicines Industry Group, we were able to engage with an important and diverse group of stakeholders in our business and to gain valuable insight into the opportunities and concerns around broader AI issues in health. This work will be captured by Talking Medicines as we continue to strive to be transparent, honest, and ethical about all aspects of our work in this important and sensitive area.”
Scott Crae’s presentation to EMIG highlighted the transformative potential of AI in healthcare and the importance of ethical considerations. Through the demonstration of Drug-GPT, Talking Medicines showcased their commitment to improving patient outcomes and maintaining transparency and integrity in their work.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. The Talking Medicines mission is to be the World’s Gold Standard for Patient Intelligence by Medicine.
